Within a series of selenium-containing compounds, including the key pharmacophores of verubecestat and ebselen (a potent antioxidant activating the Nrf2 pathway, Figure 17), the derivative 22 (Figure 17) was selected as a promising multifunctional candidate for pharmacological therapy of AD [99]. Here, NFE2L2 is linked to Alzheimer disease.